Functional Neuroanatomy of Dopamine in the Striatum

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Gerfen, Charles R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Dopamine receptors; L DOPA; Mesostriatal dopamine system; Parkinson's disease

Indexed keywords

EID: 84918861699     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0002     Document Type: Chapter

References (50)

1. Carlsson A, Falck B, Hillarp NA. Cellular localization of brain monoamines. Acta Physiol Scand Suppl. 1962;56:1-28.
2. Dahlstroem A, Fuxe K. A method for the demonstration of monoaminecontaining nerve fibers in the central nervous system. Acta Physiol Scand. 1964;60:293-294.
3. Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons Life Sci. 1964;3:523-530.
4. Dahlstroem A, Fuxe K. Evidence for the existence of monoamine containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand. 1964(suppl);232:1-55.
5. Tennyson VM, Barrett RE, Cohen G, Côté L, Heikkila R, Mytilineou C. Correlation of anatomical and biochemical development of the rabbit neostriatum. Prog Brain Res. 1973;40:203-217.
6. Graybiel AM, Ragsdale CW Jr. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci USA. 1978;75:5723-5726.
7. Herkenham M, Pert CB. Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature. 1981;291:415-418.
8. van der Kooy D, Fishell G. Neuronal birthdate underlies the development of striatal compartments. Brain Res. 1987;401:155-161.
9. Gerfen CR, Baimbridge KG, Miller JJ. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc Natl Acad Sci USA. 1985;82:8780-8784.
10. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patchand matrix-directed mesostriatal dopaminergic and nondopaminergic systems. J Neurosci. 1987;7:3915-3934.
11. Gerfen CR, Baimbridge KG, Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci. 1987;7:3935-3944.
12. Jimenez-Castellanos J, Graybiel AM. Subdivisions of the dopamine containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix. Neuroscience. 1987;23:223-242.
13. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009;29:444-453.
14. Gerfen CR. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J Comp Neurol. 1985;236:454-476.
15. Bolam JP, Izzo PN, Graybiel AM. Cellular substrate of the histochemically defined striosome/matrix system of the caudate nucleus: a combined Golgi and immunocytochemical study in cat and ferret. Neuroscience. 1988;24:853-875.
16. Gerfen CR, Staines WA, Arbuthnott GW, Fibiger HC. Crossed connections of the substantia nigra in the rat. J Comp Neurol. 1982;207:283-303.
17. Berendse HW, Voorn P, te Kortschot A, Groenewegen HJ. Nuclear origin of thalamic afferents of the ventral striatum determines their relation to patch/ matrix configurations in enkephalin-immunoreactivity in the rat. J Chem Neuroanat. 1988;1:3-10.
18. Gerfen CR. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature. 1984;311:461-464.
19. Donoghue JP, Herkenham M. Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. Brain Res. 1986;365:397-403.
20. Gerfen CR. The neostriatal mosaic: striatal patch-matrix organization is related to cortical lamination. Science. 1989;246:385-388.
21. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429-1432.
22. Gerfen CR, Young WS 3rd. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 1988;460:161-167.
23. Pan HS, Penney JB, Young AB. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurochem. 1985;45:1396-1404.
24. Young WS 3rd, Bonner TI, Brann MR. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA. 1986;83:9827-9831.
25. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366-375.
26. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281-285.
27. LeMoine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc Natl Acad Sci USA. 1990;87:230-234.
28. LeMoine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol. 1995;355:418-426.
29. Hersch SM, Ciliax BJ, Gutekunst CA, Rees HD, Heilman CJ, Yung KK, Bolam JP, Ince E, Yi H, Levey AI. Electron microscope analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci. 1995;15:5222-5237.
30. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003;425:917-925.
31. Gong S, Doughty M, Harbaugh CR, Cummins A, Hatten ME, Heintz N, Gerfen CR. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci. 2007;27:9817-9823.
32. Bakay RA, DeLong MR, Vitek JL. Posteroventral pallidotomy for Parkinson's disease. J Neurosurg. 1992;77:487-488.
33. Lozano AM, Lang AE, Hutchison WD, Dostrovsky JO. New developments in understanding the etiology of Parkinson's disease and in its treatment. Curr Opin Neurobiol. 1998;8:783-790.
34. Birkmayer W, Hornykiewicz O. The L-dihydroxyphenylalanine L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1962;203:560-574.
35. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. Adv Neurol. 1987;45:463-467.
36. Gerfen CR, Miyachi S, Paletzi R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2MAP kinase. J Neurosci. 2002;22:5042-5054.
37. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci. 1998;18:5301-5310.
38. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367:69-93.
39. Robertson GS, Herrera DG, Dragunow M, Robertson HA. L-dopa activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra. Eur J Pharmacol. 1989;159:99-100.
40. Robertson GS, Vincent SR, Fibiger HC. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain Res. 1990;523:288-290.
41. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA. 1990;87:6912-6916.
42. Konradi C, Leveque JC, Hyman SEJ. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons (p.21) depends on postsynaptic NMDA receptors and calcium. Neuroscience. 1996;16:4231-4239.
43. Keefe KA, Gerfen CR. D1 dopamine receptor-mediated induction of zif268 and c-fos in the dopamine-depleted striatum: differential regulation and independence from NMDA receptors. J Comp Neurol. 1996;367:165-176.
44. Steiner H, Gerfen CR. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci. 1993;13:5066-5081.
45. Steiner H, Gerfen CR. Dynorphin regulates D1 dopamine receptormediated responses in the striatum: relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. J Comp Neurol. 1996;376:530-541.
46. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, Lombroso PJ, Nairn AC, Greengard P, Herve D, Girault JA. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA. 2005;102:491-496.
47. Gerfen CR, Paletzki R, Worley P. Differences between dorsal and ventral striatum in drd1a dopamine receptor coupling of dopamine- and cAMPregulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J Neurosci. 2008; 28:7113-7120.
48. Aubert I, Guigoni C, Håkansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57:17-26.
49. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Herve D, Greengard P, Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007; 7:6995-7005.
50. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87:1-9.